Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm Phase 3 study of LMIS 50 mg in advanced prostate carcinoma
2013-001790-25Phase 3Completed
- Sponsor
- Foresee Pharmaceuticals
- Start
- Jun 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in prostate cancer (PCa), sponsored by Foresee Pharmaceuticals. Primary endpoints: Safety of LMIS 50 mg, Efficacy of LMIS 50 mg and 1 more. Started Jun 2014; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2013-001790-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001790-25.